Philips Teams Up with German Startup Onelife Health to Expand its Digital Health Services in Mother and Child Care
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a partnership agreement with German digital health company Onelife Health to jointly develop innovative connected health solutions around mother and child care. Leveraging synergies between the portfolios of the two companies in this important area of consumer health, the partnership will initially focus on developing Onelife's Femisphere pregnancy and first-year-of-life guidance app. 
In the global marketplace, one size doesn't fit all. That is especially true for today's diverse and competitive startup ecosystem. Oracle Startup Cloud Accelerator is not your traditional accelerator program - it's a next-generation acceleration initiative. The program focuses on reimagining enterprise innovation through partnerships with startups that foster codevelopment and co-innovation, where we all win. 
Agfa HealthCare announces today that its health management platform, including the XERO universal image viewer, has been selected to support the joint Radiotherapy Treatment Project of the Saolta University Health Care Group and Altnagelvin Hospital, part of Western Health and Socal Care Trust. 
At the Health IT Conference (HIMSS) 2017 in Orlando, Siemens Healthineers has announced a digital platform for healthcare providers as well as for providers of solutions and services, aimed at covering the entire spectrum of healthcare. The platform is to foster the growth of a digital ecosystem linking healthcare providers and solution providers with one another as well as bringing together their data, applications and services. 
Medical researchers and IBM (NYSE: IBM) are asking the public's help in finding prospective treatments for childhood cancers, the top worldwide cause of death by disease for children. Scientists are searching for chemical drug candidates that can affect the key molecules and proteins that control cancer cells in several common childhood cancers. However, finding drug candidates is an expensive and slow process. 